Drugs / KB407
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05504837 | Jun 2023 → Dec 2026 expected | cystic fibrosis | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05095246 | Mar 2022 → Jul 2024 | cystic fibrosis | Krystal Biotech, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB407 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05504837 ↗ |
| Action | Restore | “engineered to deliver functional full-length human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to the airways” NCT05095246 ↗ |
| Route | Inhaled | “via nebulization” NCT05095246 ↗ |
| Target | CFTR | “expressing full length human CFTR” NCT05095246 ↗ |